Forbes -
17 Mar 2022 14:00

Covid-19 vaccine maker Novavax's stock has declined by about 18% over the past month, compared to the S&P 500 which remains down by about 3% over the same period. While the broader markets have been weak due to the Russian invasion of Ukraine and expected interest rate hikes by the Federal Reserve..
Share this Article